Effects of High Doses of Frusemide on Plasma and Muscle Electrolytes in Patients with Chronic Renal Failure

Nephron ◽  
1974 ◽  
Vol 13 (3) ◽  
pp. 235-244 ◽  
Author(s):  
G. Maschio ◽  
G. Mioni ◽  
A. D’Angelo ◽  
E. Ossi ◽  
E. Valvo ◽  
...  
2001 ◽  
Vol 18 (3) ◽  
pp. 171-176 ◽  
Author(s):  
J. Rodríguez ◽  
O. Quintela ◽  
M. López-Rivadulla ◽  
M. Bárcena ◽  
C. Diz ◽  
...  

1975 ◽  
Vol 3 (4) ◽  
pp. 245-250
Author(s):  
Mam Chandra ◽  
M K Mitra ◽  
N N Gupta

The results of using high doses of intravenous frusemide in the management of 28 patients suffering from chronic renal failure are presented. The results are compared with those obtained from 14 patients also suffering from chronic renal failure, who received identical ‘conservative management’ but were not treated with diuretics. Large doses of intravenous frusemide produced a satisfactory diuretic response in a higher percentage of treated patients (71%) compared with controls (36%). It was also observed that in the treated group of patients a significant diuretic response could be obtained in patients with a creatinine clearance below 4 ml per minute. The study also demonstrated that in the group of patients receiving frusemide the response was better in those who were given a progressive-dose regime; 88% of patients improved with this regime compared with 68% of patients who were treated with a fixed dose of frusemide. Transient deafness with tinnitus and vertigo were the only side-effects observed. However these effects were only seen in patients who received 1000 mg or more frusemide in one day, administered over a period of one to two hours. It is concluded that all patients suffering from chronic renal failure should be given a trial of large doses of intravenous frusemide therapy, along with other conventional measures, particularly where facilities for dialysis are not immediately available.


Nephron ◽  
1980 ◽  
Vol 26 (3) ◽  
pp. 116-120
Author(s):  
Peter Teodor Fröhling ◽  
Franciszek Kokot ◽  
Karl Vetter ◽  
Jadwiga Kuska ◽  
Ingrid Kaschube ◽  
...  

2001 ◽  
Vol 18 (3) ◽  
pp. 171-176 ◽  
Author(s):  
J. Rodriguez ◽  
O. Quintela ◽  
M. Lopez-Rivadulla ◽  
M. Barcena ◽  
C. Diz ◽  
...  

1972 ◽  
Vol 43 (6) ◽  
pp. 771-778 ◽  
Author(s):  
J. D. Swales ◽  
H. Thurston ◽  
J. E. F. Pohl

1. The defect in sodium conservation shown by patients with advanced chronic renal failure has been studied during the administration of diazoxide. 2. All nine patients showed a reduction in urinary sodium concentration to levels substantially lower than those which can normally be produced in such patients even with prolonged sodium depletion. Seven patients produced a nearly sodium-free urine. In all patients this effect could be reversed by the administration of high doses of frusemide. The fall in urinary sodium concentration was associated with a sustained fall in creatinine clearance in only two cases. 3. One patient with salt-losing renal disease showed a more modest fall in sodium concentration on treatment with diazoxide. 4. It is concluded that since the defect in sodium conservation shown by patients with chronic renal failure can be corrected without diminishing the osmotic load, it cannot be solely due to the effect of the osmotic diuresis upon residual functioning nephrons. It is suggested that the distal tubular transport mechanism for sodium is saturated by the increased delivery of sodium from the proximal tubule.


2002 ◽  
Vol 22 (5-6) ◽  
pp. 445-454 ◽  
Author(s):  
Kenneth R. Phelps ◽  
Marc Stern ◽  
Alice Slingerland ◽  
Mahin Heravi ◽  
David S. Strogatz ◽  
...  

1982 ◽  
Vol 20 (25) ◽  
pp. 100.2-100

Potassium Citrate Mixture is sometimes used to make the urine alkaline but tastes unpleasant. Effervescent tablets (Effercitrate - Typharm) have recently been introduced as a palatable and more convenient alternative. One tablet contains the equivalent of 5 ml of the Mixture BPC 1973 (13.9 mmol potassium) in a lemon-flavoured effervescent base. Effercitrate may prove more acceptable than the mixture when urinary alkalinization is needed as in patients with post-irradiation cystitis,1 in certain urinary infections, and to prevent crystalluria during treatment with high doses of sulphonamides or methotrexate. Both preparations should be avoided in patients with chronic renal failure.


Sign in / Sign up

Export Citation Format

Share Document